Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Revenue

Lineage Cell Therapeutics had revenue of $3.78M in the quarter ending September 30, 2024, with 203.29% growth. This brings the company's revenue in the last twelve months to $8.72M, down -0.60% year-over-year. In the year 2023, Lineage Cell Therapeutics had annual revenue of $8.95M, down -39.16%.

• Revenue (ttm): $8.72M
• Revenue Growth: -0.60%
• P/S Ratio: 13.53
• Revenue / Employee: $116,253
• Employees: 75
• Market Cap: 121.12M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%
Dec 31, 2019	3.52M	-1.47M	-29.53%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.